Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Viewpoints - The report highlights the strong performance of the retail and beauty sectors, with a focus on the growth potential of domestic brands in the beauty industry [6][44] - The medical beauty segment is expected to see new growth drivers from innovative products, while the cosmetics sector is benefiting from the rise of domestic brands and consumer trends towards self-care [6][44] Summary by Sections 1. Market Review - The beauty and personal care index rose by 6.84% in August 2025, ranking 15th among all primary industries, underperforming the broader market which saw a 7.97% increase [12][15] - In the medical beauty sector, notable stock performances in August included Meili Tianyuan Medical Health (+32.4%), Kedi (+31.7%), and Yisi Health (+22.7%) [16] - In the cosmetics sector, leading performers were Jiaheng Home (+55.4%), Shuiyang Co. (+36.3%), and Ruoyu Chen (+29.0%) [20] 2. Medical Beauty - Jinbo Biological's "Recombinant Type III Humanized Collagen Freeze-Dried Fiber" received drug auxiliary material registration, marking a significant advancement in the medical field [26] - Longzi Co. plans to acquire 67.5% of Chongqing Milan Baiyu for 92.475 million yuan, with performance commitments ensuring net profits of at least 9.29 million yuan, 9.89 million yuan, and 11.83 million yuan from 2025 to 2027 [28] 3. Cosmetics - Proya plans to list in Hong Kong, potentially becoming the first A+H share beauty company, which would enhance its international business development [32] - Proya's investment in Huazhi Xiao will strengthen its position in the makeup sector, leveraging Huazhi Xiao's content operations and overseas channels [35] - The launch of the NAN beauty brand by Shangmei Co. represents a strategic move to enhance its presence in the mid-to-high-end market [40] 4. Investment Recommendations - The report recommends focusing on leading domestic beauty brands that are continuously evolving and capitalizing on high-growth segments [44] - Key recommendations include Shangmei Co., Maogeping, Proya, and Runben Co., with an emphasis on their strong market positions and growth potential [48]

Investment Rating - The report maintains an "Overweight" rating for the industry, with a focus on new consumption sectors such as beauty care, IP derivatives, and gold jewelry [5][28]. Core Insights - The report highlights significant market movements, with the retail trade, social services, and beauty care sectors showing varied performance, ranking 19th, 27th, and 25th respectively among 31 primary industries during the week of September 8-12, 2025 [14][16]. - Key events include Huaxi Biological's strategic investment in Saint Pharma, which focuses on small nucleic acid drugs, and Jinbo Biological's approval for a new injectable collagen product [3][23]. - The report notes a substantial increase in domestic and international flight searches ahead of the Mid-Autumn Festival and National Day holidays, indicating a recovery in travel demand [4][24]. Summary by Sections 1. Weekly Market Review - The retail trade sector increased by 0.85%, while social services and beauty care sectors decreased by 0.28% and 0.23% respectively, compared to the Shanghai Composite Index's increase of 1.52% [14][16]. 2. Key Industry Data and News - The Chinese government allocated 100 billion yuan for childcare subsidies and plans to gradually implement free preschool education [3][23]. - Huaxi Biological invested approximately 138 million HKD in Saint Pharma, acquiring a 9.44% stake, while Jinbo Biological's new collagen product is the first of its kind to enter the pharmaceutical excipient market [23][24]. 3. Key Company Announcements - Jinbo Biological announced management changes, with founder Yang Xia appointed as CEO, and plans for a cash acquisition by Langzi Co. for a controlling stake in a cosmetic surgery hospital [27][28]. 4. Investment Recommendations - The report recommends focusing on companies such as Shangmei Co., Juzi Biological, and Marumi Biological, among others, as potential investment opportunities in the beauty care and new consumption sectors [5][28].

Investment Rating - The report assigns an "Outperform" rating to multiple companies in the discretionary sector, including Nike, Midea Group, JD Group, Haier Smart Home, Anta Sports, Gree Electric, and others [1]. Core Insights - The gambling sector continues to show strong performance in September, outperforming other discretionary sub-sectors, with a weekly increase of 1.8% [4][16]. - Domestic cosmetics and luxury goods also performed positively, with increases of 0.7% and 0.3% respectively, while other sectors like overseas sportswear and snacks faced declines [4][16]. - The report highlights that most sub-sectors are currently undervalued compared to their historical averages, indicating potential investment opportunities [20]. Summary by Relevant Sections Weekly Performance Review - The gambling sector led the weekly performance with a 1.8% increase, followed by domestic cosmetics at 0.7% and luxury goods at 0.3%. In contrast, overseas sportswear and snacks saw declines of 3.0% and 4.1% respectively [4][16]. - Year-to-date performance shows significant gains in gold and jewelry, domestic cosmetics, and pets, with increases of 167.1%, 60.6%, and 38.8% respectively [13]. Sector Analysis - The gambling sector's strong performance is attributed to better-than-expected results during the off-season, with optimism for the upcoming peak season driven by events like the NBA and concerts [6][16]. - Domestic cosmetics are benefiting from successful marketing campaigns, with notable sales figures reported [6][17]. - The overseas sportswear sector is under pressure due to disappointing earnings forecasts and competition, leading to significant stock price declines [8][17]. Valuation Analysis - Most sectors are trading below their five-year average P/E ratios, indicating potential for growth. For instance, the expected P/E for the overseas sportswear sector is 33.4 times, which is 59% of its historical average [20]. - The gambling sector's expected P/E is 34.2 times, which is 40% of its historical average, suggesting it may be undervalued [20].

Investment Rating - The report maintains a positive outlook on the long-term growth potential of Hailan Home as it plans to list in Hong Kong, which is expected to enhance its overseas market presence and strengthen its competitive edge [1][12][13]. Core Insights - Hailan Home's overseas expansion strategy has been active since 2017, with a focus on Southeast Asia, and the company aims to continue exploring new markets and channels [12][13]. - The report highlights the successful registration of recombinant type III humanized collagen protein as a pharmaceutical excipient by Jinbo Bio, marking a significant breakthrough in the application of collagen in innovative drug development [14][17]. - The retail performance of the apparel sector showed a year-on-year growth of 3.7% in July, although the growth rate decreased compared to June due to various factors including promotional effects and extreme weather [23][32]. Summary by Sections Hailan Home's Hong Kong Listing - Hailan Home announced its intention to issue shares and list on the Hong Kong Stock Exchange, which is expected to facilitate its overseas market expansion and enhance its long-term competitiveness [1][12]. - The company has opened 111 overseas stores as of mid-2025, generating a revenue of 206 million yuan, a 27.42% increase year-on-year [12][13]. Jinbo Bio's Pharmaceutical Advancements - Jinbo Bio's recombinant type III humanized collagen protein has received approval as a pharmaceutical excipient, allowing it to be used in various drug delivery systems, enhancing drug efficacy while reducing side effects [14][15][17]. - The company is positioned to leverage its first-mover advantage in the domestic market for pharmaceutical excipients, with significant growth potential in the peptide and protein drug sectors [17][18]. Apparel and Cosmetics Market Trends - The apparel retail sector experienced a 3.7% year-on-year growth in July, with a noted decline in growth rate due to promotional effects and weather conditions impacting consumer traffic [23][32]. - The cosmetics retail sector saw a recovery with a 4.5% year-on-year increase in July, reflecting a positive trend in consumer spending [32]. Investment Recommendations - The report recommends Hailan Home for its strong brand and potential for growth in the apparel sector, alongside Jinbo Bio for its innovative products in the beauty and healthcare segments [35].

Investment Rating - The investment rating for the company is "Accumulate" (maintained) [2] Core Views - The company is expected to benefit from differentiated new products contributing to revenue growth despite profit impacts from upfront expenses [5][7] - The company is a leader in the field of recombinant collagen and is anticipated to transition from a rapidly growing R&D-driven enterprise to an international biocomposite platform company [7] Financial Performance - For the first half of 2025, the company reported revenue of 859 million yuan, a year-on-year increase of 42.4%, and a net profit of 392 million yuan, up 26.6% [7] - The medical device segment achieved revenue of 708 million yuan (up 33.4%) with a gross margin of 95.0%, while functional skincare products saw revenue of 121 million yuan (up 152.4%) with a gross margin of 70.8% [7] - The company forecasts revenues of 2.24 billion yuan, 3.07 billion yuan, and 4.09 billion yuan for 2025, 2026, and 2027 respectively, with corresponding net profits of 1.09 billion yuan, 1.51 billion yuan, and 2.05 billion yuan [6][7] Business Developments - The company received regulatory approval for its "recombinant type III humanized collagen gel" injection, marking it as the first of its kind in China targeting mid-face volume loss and contour defects [7] - Strategic collaboration with Yangshengtang aims to build a new ecosystem in the biocomposite materials industry, potentially expanding into orthopedic materials and other health sectors [7] Market Performance - The company's stock has shown a performance of -12% over the last 12 months compared to the Shanghai Composite Index [4]

Core Viewpoint - Jinbo Biological has reported strong financial performance for the first half of the year, indicating significant growth in revenue and net profit, alongside a planned cash dividend distribution to shareholders [1][2][3]. Financial Performance - The company achieved a revenue of 859 million yuan, representing a year-on-year increase of 42.43% [2]. - The net profit attributable to shareholders was 392 million yuan, reflecting a year-on-year growth of 26.65% [2]. - The gross profit margin decreased slightly to 90.68% from 91.58% in the previous year [2]. - Basic earnings per share were reported at 3.41 yuan [2]. Business Growth Drivers - The revenue growth was primarily driven by increased sales in medical devices and functional skincare products [2]. - The medical device segment saw growth mainly from the sales of implant products based on type A recombinant human collagen [2]. - The functional skincare segment benefited from the sales of proprietary brands such as "重源" and "ProtYouth®" [2]. Company Background - Jinbo Biological is recognized as a national-level specialized and innovative "little giant" enterprise and a key player in the synthetic biology industry chain in Shanxi Province [3]. - The company was listed on the Beijing Stock Exchange on July 20, 2023, with an initial market capitalization of 8.757 billion yuan, which has since increased to nearly 37 billion yuan [3]. Future Prospects - The company plans to utilize funds from a recent share transfer to enhance its research and development capabilities, particularly in the area of humanized collagen products [6][7]. - The total investment for the new FAST database and product development platform project is approximately 1.26 billion yuan, with a three-year implementation period [6].

Core Viewpoint - The strategic investment actions by Jinbo Biotechnology have attracted significant attention, particularly due to the involvement of Zhong Shanshan, China's richest man, who is investing a total of 34.03 billion yuan through his companies [1][2]. Group 1: Investment Details - Jinbo Biotechnology will issue shares to Yangshengtang Co., Ltd., representing 6.24% of its total shares before the issuance, with a financing amount not exceeding 2 billion yuan [2]. - The share transfer agreement between Jinbo's controlling shareholder Yang Xia and Hangzhou Jiushi involves the transfer of 5,753,267 shares at a price of 243.84 yuan per share, totaling 1.403 billion yuan [2][3]. - After the transfer, Yang Xia will hold 50.73% of Jinbo, while Hangzhou Jiushi and Yangshengtang will hold 4.71% and 5.87%, respectively, making Zhong Shanshan the second-largest shareholder of Jinbo with 10.58% ownership [3]. Group 2: Company Overview - Jinbo Biotechnology focuses on the research, development, production, and sales of high-end implantable medical devices made from recombinant human collagen, primarily used in aesthetic medicine and skin repair [4]. - The company achieved significant revenue growth, with sales increasing from 233 million yuan in 2021 to 1.443 billion yuan in 2024, and net profit rising from 57.39 million yuan to 732 million yuan during the same period, reflecting a year-on-year growth rate of over 79% [4]. Group 3: Market Potential - The collaboration between Jinbo and Yangshengtang is expected to leverage their respective strengths in large-scale industrial production and market channel development, addressing the urgent need for a comprehensive production and sales system [5]. - The market for collagen-based skin care products is projected to surpass that of hyaluronic acid by 2026, with the overall market size for collagen in China expected to reach 173.8 billion yuan by 2027, of which recombinant collagen products will account for 1.083 billion yuan, representing 62.3% of the market [5].

Core Viewpoint - The recent stock issuance by Jinbo Biological, controlled by Zhong Shanshan, aims to raise up to 2 billion RMB to support its growth and development in the collagen market, while also indicating a strategic partnership with Yangshengtang [1][2][7]. Group 1: Company Actions and Financials - Jinbo Biological plans to issue no more than 717,566 shares, representing 6.24% of its total shares before the issuance, to raise funds for a humanized collagen protein database and working capital [1][2]. - The total investment for the projects is 200 million RMB, with 57.5% allocated to the collagen protein project and 42.5% for working capital [2]. - Jinbo Biological's stock price has surged since its listing, with a maximum increase of over 800% from its issue price, reaching a peak of 452.29 RMB [3][9]. Group 2: Market Performance and Growth - Jinbo Biological has shown impressive financial growth, with revenue increasing from 233 million RMB in 2021 to 1.443 billion RMB in 2024, and net profit rising from 57.39 million RMB to 732 million RMB in the same period [9]. - The gross margin improved from 82.29% to 92.02%, and net margin increased from 24.38% to 50.68% [9]. - The Chinese collagen market reached 28.7 billion RMB in 2021, growing at 40.7%, with a significant increase in the penetration of recombinant collagen [9]. Group 3: Strategic Partnerships and Future Outlook - Yangshengtang, controlled by Zhong Shanshan, is entering into a strategic partnership with Jinbo Biological, which is expected to enhance business synergies and accelerate the implementation of their strategic goals [7][8]. - The collaboration aims to leverage technological integration and market channel empowerment, potentially leading to significant advancements in product development [7][8]. - Jinbo Biological's need for strategic investors is highlighted by its relatively small size and the increasing competition in the medical aesthetics industry [10][13].

Market Performance - The micro-cap stock index opened lower but surged over 1% to reach a historical high before closing down 1.37% [2] - The North Exchange 50 index experienced a significant decline, closing down 6.15% after reaching a historical high the previous day [2] Reasons for Adjustment - Analysts suggest that the recent market adjustment is due to both internal and external factors, including a historical pattern where high levels of congestion in the market led to significant pullbacks [3] - The micro-cap sector may face profit-taking pressure as funds become overly concentrated, potentially shifting market preference towards mid and large-cap stocks [3] Company-Specific Insights - Jinbo Biological (832982.BJ) saw its stock price drop over 17% during the day, closing down 14.55%. The company attributed the decline to market factors rather than specific company issues [3] - Jinbo Biological's stock had been on a steady rise since March, reaching a peak of 589.98 CNY per share on May 22, with a total market capitalization exceeding 52 billion CNY [3] - The company is recognized for its innovative medical device, the "recombinant type III humanized collagen freeze-dried fiber," which is the first of its kind in China, laying a solid foundation for clinical applications and industrial transformation [4] Market Sentiment - The poor results from the U.S. 20-year Treasury auction have led to a negative sentiment in the U.S. financial markets, potentially increasing global risk aversion and cautiousness [5] - There are indications that micro-cap stock investments may be overly crowded, with trading volumes surpassing previous highs, signaling significant overbought conditions [5]

Core Viewpoint - The article highlights the significance of the New Fortune Gold Medal Secretary selection in the Chinese capital market, emphasizing the role of outstanding secretaries in enhancing corporate governance and investor relations, thus contributing to high-quality market development [1]. Company Overview - Jinbo Biological was established in 2008 and is headquartered in Taiyuan, Shanxi. It is recognized as a national-level specialized and innovative "little giant" enterprise and a key player in the synthetic biology industry chain in Shanxi Province. The company focuses on the research and industrialization of recombinant humanized collagen [5]. Key Achievements - Jinbo Biological became the first A-share listed company in China centered on "recombinant humanized collagen" after successfully completing its listing on July 20, 2023, on the Beijing Stock Exchange. This milestone serves as a model for the industrialization of original achievements by small and medium-sized enterprises in China [3]. - The company has received multiple approvals for innovative medical devices, including the first medical device product in China using new biological materials, and has established itself as a leader in the production of implant-grade medical devices globally [6][7]. Technological Breakthroughs - Jinbo Biological has achieved three core technological breakthroughs: 1. Safety breakthrough with a protein amino acid sequence highly consistent with natural collagen, showing strong biocompatibility and no immunogenic issues in over 2 million clinical applications [8]. 2. Effectiveness breakthrough with a clear 164.88° flexible triple helix structure, recognized by the international protein database [8]. 3. Application scenario breakthrough with high cell adhesion surpassing natural collagen, demonstrating excellent tissue repair characteristics across various fields [8]. Innovation Strategy - The company adheres to an "original innovation" strategy, having established six major technology platforms and multiple joint research platforms with prestigious institutions, covering the entire chain from basic research to clinical transformation and industrial implementation [9]. Role of the Secretary - The role of the board secretary is crucial in bridging the company and the capital market, requiring solid financial and legal knowledge, as well as excellent communication and coordination skills. The secretary's responsibilities include ensuring compliance, enhancing communication with regulatory bodies, investors, and media, and fostering a transparent public relations environment [14].